Docetaxel in Treating Patients With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
PURPOSE: Phase II trial to compare the effectiveness of docetaxel in treating Caucasian and African American patients who have solid tumors.
Head and Neck Cancer
Unspecified Adult Solid Tumor, Protocol Specific
|Study Design:||Primary Purpose: Treatment|
|Official Title:||A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and African-American Cancer Patients|
|Study Start Date:||September 1998|
|Study Completion Date:||January 2008|
|Primary Completion Date:||January 2006 (Final data collection date for primary outcome measure)|
- Compare the population pharmacokinetics of docetaxel in Caucasians and African American patients with solid tumors.
- Compare the pharmacodynamic effect of a single dose of docetaxel in relation to hematological toxicity in these patient populations.
- Determine the CYP3A4 genotype and P-glycoprotein (P-gp) expression and their relationship to docetaxel clearance in these patient populations.
OUTLINE: Patients receive docetaxel IV over 1 hour on day 1. Patients may receive additional courses beginning 21 days after the first docetaxel dose at the discretion of the physician.
PROJECTED ACCRUAL: Approximately 80 patients (40 Caucasian and 40 African American) will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00003565
Show 74 Study Locations
|Study Chair:||Lionel D. Lewis, MD||Norris Cotton Cancer Center|